Floatz logo

Peg-L-Asparaginase

Mixed Lineage Acute Leukemia

St. Jude Children's Research HospitalPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

72 Active assets in the Mixed Lineage Acute Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
St. Jude Children's Research Hospital
Phase 4BB
METHOTREXATE
Children's Oncology Group
Phase 4BB
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3BB
DEXAMETHASONE
St. Jude Children's Research Hospital
Phase 4BB
Cytosin-Arabinosid
Children's Oncology Group
Phase 4BB

View all 50 →

Same molecule, other indications

Peg-L-Asparaginase is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
55 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Refractory T-Cell LymphomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →